Merck’s WINREVAIR shows promise in phase 2 study for hard-to-treat pulmonary hypertension
The drug is being tested for combined post- and precapillary pulmonary hypertension due to heart failure with preserved ejection fraction
The drug is being tested for combined post- and precapillary pulmonary hypertension due to heart failure with preserved ejection fraction
The 2025 edition of the EdelGive Hurun list recognizes 24 exceptional women leaders for their philanthropic impact across critical areas
Innovent plans to soon submit a new drug application (NDA) to China’s National Medical Products Administration
The move is expected to be crucial during health crises
The study met its primary endpoint, demonstrating a statistically significant and clinically meaningful improvement in invasive disease-free survival
EBITDA was Rs. 2,359.6 crore in the quarter ended September 30, 2025
The FDA is initiating removal of the boxed warnings following a comprehensive review of the scientific literature
Cardiovascular disease (CVD) is the leading cause of death in the US and worldwide with over 82 million Americans living with CVD
FIBROSARC did not meet its primary PFS endpoint in the final analysi
Subscribe To Our Newsletter & Stay Updated